Biohaven Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Biohaven Pharmaceuticals's estimated annual revenue is currently $307.6M per year.
- Biohaven Pharmaceuticals received $143.7M in venture funding in December 2018.
- Biohaven Pharmaceuticals's estimated revenue per employee is $590,422
- Biohaven Pharmaceuticals's total funding is $443.7M.
- Biohaven Pharmaceuticals's current valuation is $8B. (January 2022)
- Biohaven Pharmaceuticals has 521 Employees.
- Biohaven Pharmaceuticals grew their employee count by -46% last year.
Biohaven Pharmaceuticals Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Biohaven Pharmaceuticals?
Biohaven is engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. Biohaven obtained licenses from Yale University School of Medicine and Massachusetts General Hospital regarding intellectual property relating to the use of certain glutamate modulating agents in the treatment of neuropsychiatric disorders. The mission of the company is to exploit advances over the past decade in the understanding of glutamate mechanisms involved in a variety of diseases. The company's first drug candidate is being developed for orphan neurological disorders as well as treatment-resistant anxiety and depression. Biohaven has assembled a team of experts who have extensive experience in the development of therapeutic agents in this area and also comprise the originators at Yale University who discovered the therapeutic potential of glutamate modulation in anxiety and depression. Team members have designed and executed successful development programs testing a variety of agents in affective disorders, leading to first-cycle FDA approvals and successful commercialization.keywords:N/A
Number of Employees
Employee Growth %
Biohaven Pharmaceuticals News
The European Commission approved Biohaven Pharmaceuticals migraine drug rimegepant. While the regulatory decision marks another milestone for...
Biohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of...
Looking to reach patients with a wide range of migraine symptoms in Europe, Pfizer and Biohaven are first on the scene with an oral CGRP...
NEW HAVEN, Conn. and NEW YORK, Nov. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval. Rimegepant is commerc ...
MOORESVILLE, N.C., Nov. 2, 2021 /PRNewswire/ -- Rick Ware Racing (RWR) has joined forces once again with Nine Line Apparel and Biohaven Pharmaceuticals' Nurtec® ODT (rimegepant) to pay tribute and honor the upcoming 80th Anniversary of the Attack on Pearl Harbor this weekend at Phoenix Raceway f ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Biohaven Pharmaceuticals Funding
|2018-12-13||$143.7M||Undisclosed||Goldman Sachs & Co. LLC||Article|